New pharmacological agents such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are showing promise in managing heart failure with preserved ejection fraction (HFpEF) in elderly patients [37]. The gene discussed is SLC5A2; the disease is heart failure.